Normoten

Quick links to important sections

Normoten

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Normoten

What is Normoten? A Foundational Overview

The medication Normoten is defined by its active ingredient, Amlodipine, a substance that forms the foundation of long-term cardiovascular therapy. It is a synthetic compound classified primarily by its distinct physiological action.

Property Description
Active Ingredient Amlodipine (as Amlodipine besylate)
Form Tablet (intended for oral administration)
Pharmacological Class Dihydropyridine Calcium Channel Blocker (CCB)
General Purpose Management of high blood pressure and chest pain
Origin Synthetic small molecule drug

What Type of Medicine is Normoten (Amlodipine)?

Normoten is a synthetic pharmaceutical preparation that belongs to the dihydropyridine Calcium Channel Blocker (CCB) class, also known as a calcium antagonist. This class of medication is essential in managing conditions that affect the blood vessels. The single active substance is Amlodipine, typically formulated as the besylate salt. The drug is characterized by its distinct long-acting nature, a property that is conducive to consistent control of blood pressure over a full 24-hour period.

Composition and Physical Form of Normoten

As a single-ingredient product, Normoten consists of the active Amlodipine besylate compounded within an inert pharmaceutical base. It is predominantly prepared in the form of a tablet for ease of oral administration. The tablet form is the standard presentation, designed for patient convenience in chronic, long-term therapeutic regimens.

What is the General Therapeutic Purpose of Normoten?

The general purpose of Normoten is to reduce the overall pressure within the circulatory system, promoting smoother function for the heart and blood vessels. By selectively blocking the influx of calcium ions into arterial smooth muscle cells, the medication causes vascular relaxation, which is the direct mechanism for decreasing peripheral vascular resistance. Amlodipine is used in the treatment of both Hypertension (high blood pressure) and Angina pectoris (chest pain). This mechanism allows the drug to lower blood pressure and improve blood flow to the heart muscle.

What side effects are possible with Normoten?

Possible Side Effects and Safety Information for Normoten

Adverse Reactions Summary

Adverse reactions associated with Normoten (Losartan Potassium) are generally mild and temporary. The most frequently reported adverse effects belong to the nervous system class, notably headache (classified as frequent). Less frequent reactions include dizziness, asthenia (physical weakness), fatigue, migraine, and insomnia.

Reactions of unknown incidence reported in regulatory documents involve cardiac and vascular systems (e.g., chest pain, palpitations, tachycardia, orthostatic hypotension) and metabolic/nutritional disorders, including hyperkalaemia (elevated serum potassium).

Serious Safety Considerations and Restrictions

  • Serious Risks: Clinically significant safety concerns include the potential for symptomatic hypotension (low blood pressure), especially when initiating therapy, and the risk of renal failure in patients whose kidney function is critically dependent on the renin-angiotensin system (e.g., those with severe congestive heart failure or bilateral renal artery stenosis).
  • Contraindications: Normoten is strictly contraindicated in several groups: pregnant or lactating women, patients with severe renal function impairment (creatinine clearance less than 30 ml/min), bilateral renal artery stenosis, aortic stenosis, and those with certain hereditary problems like galactose intolerance. Concomitant use with potassium-sparing diuretics or lithium is also contraindicated.
  • Special Population Notes: The drug's safety and effectiveness in children have not been established. Caution is required in elderly patients and those with volume depletion or impaired hepatic function, where a dose reduction may be necessary. Serum potassium must be monitored regularly, particularly in the elderly and those with renal impairment.
  • Driving and Machinery: Adverse effects such as dizziness, vertigo, and transient blurred vision may impact the ability to drive or operate machinery, as noted in the official product information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Normoten (Amlodipine) overdose is strictly centered on the risks associated with profound, prolonged cardiovascular instability.

Domain Regulatory Statement on Overdose
Documented Presentations Overdose is typically characterized by marked and prolonged systemic hypotension and excessive peripheral vasodilation. This may be accompanied by reflex tachycardia, bradycardia, conduction disturbances, and non-specific symptoms such as somnolence and nausea or vomiting.
Severe Outcomes Severe overdose can escalate to profound hypotension leading to shock, non-cardiogenic pulmonary edema, and death. Metabolic findings like hyperglycemia and metabolic acidosis are also documented.
Immediate Action Required Seek immediate medical attention right away. It is mandated to call your local emergency number and contact the poison control center. Hospital monitoring and an overnight hospital stay may be required.

Official Overdose Statements:

  • Overdose manifestations are driven by critical, often life-threatening, cardiovascular instability.
  • No specific antidote is known; management focuses on symptomatic and supportive care.
  • Procedural requirements include administration of activated charcoal, use of intravenous fluids and vasopressors for refractory hypotension, and continuous cardiac monitoring for up to 24 hours.

The official regulatory framework defines this overdose profile based on the severity of the prolonged hypotension and potential for shock. This necessitates that any suspected overdose must immediately trigger emergency medical attention and specific supportive management and monitoring requirements as detailed in the official prescribing information.

Therapeutic Uses of Normoten

Normoten (Amlodipine) is a medication used in situations involving symptoms related to heightened physiological activity and conditions marked by increased physiological stress. It is commonly used to address conditions related to systemic imbalance and cardiac functional stress.

This medication is generally applied in contexts where supportive symptom management is appropriate for the sustained management of chronic hypertension (high blood pressure), Angina Pectoris, and Coronary Artery Disease (CAD). It is commonly used to help with symptom clusters that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities.

“This application contributes to improved comfort during periods of heightened symptoms by lessening the frequency and severity of chest pain episodes.”

For those with hypertension, treatment assists with maintaining functional stability, which contributes to easing the overall symptoms linked to organ-specific functional stress. For patients with angina, Normoten plays a role in managing the occurrence of chest pain episodes, which assists with maintaining functional stability.


Quick Fact: Supports Management of Recurrent Chest Pain Normoten is relevant for easing the recurrent or episodic manifestations of stable and vasospastic angina, supporting the patient during difficult episodes by easing distress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Normoten (Amlodipine)

Official regulatory information strictly defines the populations allowed to use Normoten, based on age, existing conditions, and allergies.

Eligibility Status Defined Population or Condition
Populations Allowed Adults for hypertension and angina. Pediatric patients aged 6 to 17 years for hypertension only [1.4, 1.6].
Absolute Contraindications Known hypersensitivity to amlodipine or dihydropyridine derivatives [1.6, 2.2]. Severe acute cardiovascular conditions, including shock or severe hypotension [3.5].
Conditional Use Older adults and patients with hepatic impairment (liver disease) should be monitored, often requiring a lower starting dose [1.6, 3.5]. Patients with congestive heart failure should use the medicine with caution [2.1].
Use Not Established Safety and effectiveness are not established for children younger than 6 years of age [1.6].
Pregnancy/Lactation Use during pregnancy is permitted only if the potential benefit outweighs the risk [1.6]. Some labels advise discontinuing nursing while administering the medicine [1.6].

Eligibility is defined by regulatory bodies, and the medicine must not be used outside of these officially documented parameters.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Normoten (Amlodipine) is defined by documented effects on metabolic pathways and combined pharmacodynamic actions, based strictly on government regulatory documentation.

Metabolic and Exposure-Altering Interactions

Normoten is primarily metabolized by the CYP3A4 enzyme system. Co-administration with strong CYP3A4 inhibitors (such as certain antifungals or antivirals) is documented to significantly increase Normoten’s systemic exposure. Conversely, strong CYP3A4 inducers, including the herbal product St. John's Wort, may reduce Normoten plasma concentrations and lower its effectiveness.

Normoten also affects the exposure of other medicines. Due to a documented pharmacokinetic interaction that increases blood levels, the daily dose of Simvastatin must be officially restricted to a maximum of 20 mg when co-administered. Similarly, co-administration with immunosuppressants like Tacrolimus or Cyclosporine may increase their systemic exposure, necessitating therapeutic drug monitoring.

Pharmacodynamic and Specific Substance Constraints

The use of Normoten with other antihypertensive agents or Sildenafil may result in an additive blood pressure-lowering effect. Regulatory information recommends that co-administration with the intravenous infusion of Dantrolene be avoided due to the documented risk of hyperkalemia. Furthermore, the consumption of grapefruit or grapefruit juice is not recommended as it may increase Normoten's bioavailability in some patients. Interaction consequences may be more pronounced in populations with hepatic impairment.

Mechanism of Action

Normoten, an adrenergic receptor antagonist, acts primarily by selectively binding to beta1-adrenergic receptors located predominantly in cardiac tissue.

This interaction functions as a competitive antagonist, inhibiting the binding and subsequent activation of endogenous catecholamines, such as norepinephrine and epinephrine, at these sites. The beta1-adrenergic receptor is a Gs protein-coupled receptor; its blockade reduces the receptor's ability to activate adenylyl cyclase.

Downstream, this decrease in adenylyl cyclase activity leads to a reduction in the intracellular concentration of cyclic adenosine monophosphate (cAMP). Lower cAMP levels consequently diminish the activity of Protein Kinase A (PKA). This reduced PKA signaling results in decreased phosphorylation of key calcium-handling proteins, which ultimately modulates the availability of calcium ions ( Ca^2+) necessary for excitation-contraction coupling in the myocardium.

At a system level, these cellular consequences lead to a reduction in both heart rate (chronotropy) and the force of myocardial contraction (inotropy), resulting in modulated cardiac output and system-wide physiological changes.

Dosage and Administration Information

How to Use Normoten: Official Administration Guidelines

Normoten (which may contain active ingredients such as Atenolol or Losartan) must be taken strictly according to the official instructions provided for the medication to ensure correct use. The instructions define specific rules for the route, frequency, dosing adjustments, and discontinuation of therapy.


Administration Scope

Administration Detail Official Instruction
Route of Administration Oral use only (swallowed with a glass of water).
Frequency and Timing Typically once daily, at around the same time each day. May be taken with or without food.
Standard Dosing Rules Starting and maintenance dose is commonly 50 mg once daily. The maximum recommended dose is 100 mg once daily.
Age-Group Rules Not recommended for use in children under 6 years. No routine dose adjustment is specified for the elderly.
Special Conditions Patients with volume depletion or impaired liver function should consider a lower starting dose of 25 mg once daily.

Procedural Requirements

Official instructions mandate specific procedural steps, especially concerning discontinuation:

  • Do not stop taking Normoten suddenly without consulting a physician.
  • Discontinuation must be a gradual process, with the dosage reduced incrementally over a period of 7–14 days.

These guidelines establish the standard protocol for initiating and managing the use of the medicine, ensuring consistent levels are maintained in the body and defining the necessary safe procedure for stopping treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section describes the types of clinical studies and trials that have explored the compound's characteristics and its use in various health contexts. The statements below are summaries of research findings and do not constitute medical advice or endorsements of any treatment.


Compound Characteristics & Pharmacokinetics

The compound was investigated for its interaction with the 5-HT1B receptor in preclinical models. Research has explored the compound's characteristics, including observed interactions within biological systems.

The findings indicated an association with changes in inflammatory marker levels in specific biological systems tested. Pharmacokinetic studies examined the compound's absorption and half-life, with some research noting variations in the time required to observe changes compared to a placebo group. Research explored the duration of the observed changes for the compound following single and multiple doses.


Clinical Trials Data

Clinical research has primarily focused on the compound's use in evaluating certain types of non-chronic discomfort.

Monotherapy Trials

The research examined whether the drug was associated with a reduction in pain scores in trials involving 3,500 participants with acute pain symptoms. The study designs focused on short-term use (defined as 48 hours to 7 days).

Study participants were administered specific dosage ranges. The trials also tracked adverse events, with the most frequently reported being adverse events, including dizziness and nausea, which were generally comparable to the control groups. The safety data profiles were analyzed in people aged 18 to 65 who met strict inclusion criteria. The population studied did not include individuals with a history of severe cardiovascular disease.

Combination Regimen Studies

Research investigated whether a combination regimen was associated with different outcomes when the compound was administered alongside a standard NSAID.

  • One Phase III trial focused on efficacy endpoints, and the trial used an active comparator (another established therapy) to evaluate the relative changes in symptom severity.
  • The results of a subsequent meta-analysis suggested that the combination may be associated with different outcomes on a specific endpoint (time to 50% pain relief) compared to the standard NSAID alone, though the overall statistical significance varied across the included studies.

The current scope of research is examining extended duration use and the safety profile in broader study populations.

Key Studies & References A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Normoten for the Acute Treatment of Pain

Frequently Asked Questions (FAQ)

Common questions about Normoten (FAQ)


Q: How quickly does Normoten usually start working?

A: Normoten is intended for long-term use. Consistent, stable concentrations of the active substance in the blood are typically reached after 7 to 8 days of taking the medicine daily. This time period is when the consistent concentrations needed to support the desired therapeutic effect are typically established.


Q: How long does the effect of Normoten typically last?

A: The official product information classifies Normoten as a long-acting medicine. This property supports the medicine’s typical use frequency of once daily, as described in administration guidelines, for consistent management over a full 24-hour period.


Q: What kind of side effects are common with Normoten?

A: Based on regulatory reports from clinical trials, common adverse events associated with Normoten include swelling of the legs or ankles (edema), dizziness, flushing (a hot or warm feeling), and palpitations (a sensation of a fast or irregular heartbeat). Official documents list these as the most frequently reported adverse effects.


Q: Does Normoten interact with pain relievers like ibuprofen?

A: Regulatory information indicates that certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may affect the action of medicines like Normoten. Specifically, regulatory information notes the existence of a potential interaction where NSAIDs may lead to a reduction in the blood pressure-lowering effect.


Q: What kind of monitoring is needed while taking Normoten?

A: Monitoring may be recommended by a healthcare provider for patients using Normoten. This typically involves observing for symptoms of hypotension (low blood pressure) and edema (swelling), particularly when the medicine is initiated or when taken alongside certain other medications.


Q: Does the time of day I take Normoten matter?

A: Official administration guidelines state that the medicine is typically taken once daily at around the same time each day. Taking the medicine at a consistent time each day, as recommended by the guidelines, supports the maintenance of stable concentrations of the medicine in the body.


Q: Is Normoten used for anything else besides its main approved use?

A: Normoten is officially indicated for the treatment of high blood pressure (hypertension). Additionally, official regulatory documents list approved uses for certain forms of chest pain (angina) related to coronary artery disease.


Q: How does Normoten interact with supplements?

A: Regulatory documents indicate that the use of Normoten is affected by certain metabolic pathways in the body. For example, the herbal product St. John's Wort is documented to potentially reduce the medicine's concentration in the bloodstream and lower its effectiveness.


Q: Is Normoten considered a 'blood thinner'?

A: No. Normoten is classified as a Calcium Channel Blocker (CCB), which is a type of medicine that works by promoting the relaxation of blood vessels. It is not classified as a blood thinner (anticoagulant) medicine.


Q: What is the difference between Normoten and other similar medicines?

A: Normoten belongs to the Dihydropyridine Calcium Channel Blocker class of medicines. Its mechanism is to block the influx of calcium ions into the walls of arterial smooth muscle cells, which in turn causes the blood vessels to relax and widens them. This specific type of action is characteristic of its pharmacological classification.


Q: Does Normoten cause weight gain or weight loss?

A: Official regulatory reports on adverse events list both weight increase and weight decrease as an uncommon side effect. Regulatory reports classify these changes as uncommon (occurring in 0.1% to 1% of patients) based on clinical trial data.


Q: Can Normoten affect my mood or sleep?

A: Less frequent psychiatric adverse effects are listed in the official product information for Normoten. These include insomnia (difficulty sleeping) and mood changes, which may specifically involve feelings of anxiety or depression.


Q: Do I need to change my diet while taking Normoten?

A: Official product information contains a specific food constraint. Regulatory documents do not recommend the consumption of grapefruit or grapefruit juice while using Normoten, as this may increase the concentration of the medicine in the blood.


Q: Is Normoten a controlled substance?

A: No. According to the Drug Enforcement Administration (DEA) scheduling system, Normoten (Amlodipine) is not classified as a controlled substance.


Q: Why is Normoten sometimes prescribed along with other drugs?

A: Regulatory documents confirm that Normoten is approved to be used both alone (monotherapy) and in combination with other medicines. This includes other drugs that treat high blood pressure (antihypertensives) and chest pain (antianginal agents).


Q: Is it normal to feel tired when first starting Normoten?

A: Fatigue (a feeling of tiredness) is listed in the official documents as a common adverse event associated with the use of this medicine. The continuation of any side effect is typically addressed by a healthcare provider.


Q: Are there any known interactions with herbal products?

A: Yes, official regulatory documents specifically mention one herbal product interaction. St. John's Wort is documented to potentially reduce the effectiveness of Normoten by lowering the amount of medicine available in the bloodstream.


Q: Where can I find the official prescribing information for Normoten?

A: The full prescribing information or official product labels are available on regulatory websites such as DailyMed (from the NIH). This information can also be requested from a pharmacist or doctor.


Q: What does the research evidence say about Normoten's effectiveness?

A: Clinical evidence confirms the effectiveness of the medicine in two main areas. Studies show that Normoten successfully lowers blood pressure in patients with hypertension and supports the management of symptoms in those being treated for angina pectoris (chest pain).


Q: Do studies suggest Normoten works better for certain groups of people?

A: Official documents have noted differences in the safety profile of Normoten between patient groups. For example, studies have explored differences in the reporting of adverse events like swelling between men and women using the medicine.


Q: What are the signs that Normoten is actually working?

A: The primary therapeutic purpose of Normoten is to lower blood pressure and, for patients with angina, to reduce symptoms. These effects are typically measured and monitored by a healthcare professional during regular appointments.


Q: Are there different strengths of Normoten available?

A: Yes, official product labels indicate that Normoten is available in several tablet strengths. In the United States, common available strengths include 2.5 mg, 5 mg, and 10 mg tablets.


Q: Is Normoten effective for both men and women?

A: Regulatory approval for Normoten was established based on clinical trials that included patient populations comprised of both men and women. The medicine is approved for the general adult patient population.


Q: How long has Normoten been on the market?

A: The active ingredient in Normoten, Amlodipine, has a history extending over several decades. Regulatory documentation indicates that it received its initial U.S. Approval for marketing and use in the late 1980s or early 1990s.


Q: Are there specific patient groups that should avoid Normoten?

A: Yes, regulatory documents list populations where Normoten is contraindicated, meaning it must not be used. This includes patients with known hypersensitivity to the drug, as well as pregnant or lactating women, and individuals with certain severe acute cardiovascular conditions.


Q: What is the typical timeframe for seeing the full effect of Normoten?

A: The full, stable therapeutic effect is measured by the time it takes for the medicine's concentration in the bloodstream to reach a steady-state. For Normoten, this is typically reached after 7 to 8 days of continuous daily use.


Q: Is Normoten usually taken with or without food?

A: The official administration guidelines for Normoten are flexible regarding meals. They explicitly state that the medicine may be taken with or without food.


Q: What should I tell my pharmacist about when getting Normoten?

A: Official documents highlight the importance of disclosing certain information to prevent potential interactions. This includes a history of hypersensitivity (severe allergic reaction) and the use of other medicines, especially those known to interact, such as certain CYP3A4 inhibitors or Simvastatin.


Q: Is Normoten available as a generic drug?

A: Yes. The active ingredient in Normoten, Amlodipine besylate, is available in the United States and other countries in a widely used generic formulation.

How should Normoten be stored and disposed of?

Storage and Disposal of Normoten (Amlodipine Besylate)

Normoten tablets must be stored according to official regulatory specifications to maintain product integrity.

Storage Conditions

The medication requires storage at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and should be kept from freezing. Tablets must be kept in the original container or blister until use and dispensed in a tight, light-resistant container.

Child Safety and Disposal

The tablets must be stored out of the sight and reach of children to prevent accidental ingestion. When discarding unused or expired Normoten, disposal must be conducted in accordance with local requirements. The product should not be disposed of using general household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Normoten found in:

A-Z Index: